News

The U.S. Food and Drug Administration on Thursday publicly shared over 200 archived so-called complete response letters ...
By Stephanie Brown HealthDay ReporterTHURSDAY, July 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided an in-depth view | ...
The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are ...
The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.
FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.
The FDA on Thursday said it published more than 200 decision letters, known as complete response letters, that it issued in response to applications for approval of drugs or biological products ...
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...